 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.020.285 |
| Chemical and physical data | |
| Formula | C30H35F2N3O |
| Molar mass | 491.627 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 159 to 161 °C (318 to 322 °F) |
| Solubility in water | Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C) |
| |
| |
 N Y (what is this?) (verify) | |
Lidoflazine is apiperazinecalcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered atJanssen Pharmaceutica in 1964. In 2025 Lidoflazine has also been reported to interact withtubulin and inhibit its polymerization.[2]
Extracted from[1]
| Solvent | 0.01 N | 0.1 N | ||
| % | pH | % | pH | |
| Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
| Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
| Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
| Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
| Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |